Is Really Ra Medical Systems a Good Penny Stock to Buy?

The shares of commercial-stage medical tool manufacturer Ra Medical Systems (RMED) have tumbled 92.7% in price over the past year because of capitalist worries surrounding the company’s poor monetary health and wellness. Additionally, given the uncertainty bordering the FDA’s authorization of its DABRA catheter laser system, the question becomes, is the penny stock a winner currently? Keep reading, let’s find out.

Medical gadget business Ra Medical Systems, Inc. (RMED – Get Ranking) in Carlsbad, Calif., is styles, develops, and markets excimer lasers to treat vascular diseases. The business has made substantial progression in key initiatives, including its DABRA modern technology laser system and atherectomy pivotal clinical research study. Nevertheless, the stock RMED has actually declined 86.8% in price over the past six months and also 92.7% over the past year, reflecting financier concerns over its frustrating income and earnings growth and also the sale of its dermatology company.

Closing yesterday’s session at $0.42, the stock is presently trading 95.7% below its 52-week high of $9.82, indicating bearish view.

While the commercial-stage medical gadget company has filed a 510( k) application with the U.S. Fda (FDA) for its DABRA catheter, its commercialization potential customers continue to be unclear up until its item receives approval from the FDA. Moreover, the stock’s unfavorable profitability could make financiers anxious.

Marketing Shares

Last month, RMED valued an underwritten public offering of units of its common stock, including warrants to buy up to 27.6 million shares of the ordinary shares as well as pre-funded warrants to acquire as much as 14.47 shares of penny stocks. The medical gadget manufacturer expects approximately $12.1 million in gross proceeds from the offering.

Divestiture of Dermatology Service

Leading 10 Stocks for 2022
In the 3rd quarter, RMED completed the sale of its Pharos dermatology company for net earnings of around $3.5 million. This was done as a part of the company’s plans to concentrate its resources on the marketplace for medical gadgets to deal with outer artery disease (PAD). Nevertheless, the divestiture could negatively influence the medical tool manufacturer’s profits and also expense framework in the near term and also cause RMED’s stock cost to roll even more.

Stark Profitability

The business’s trailing-12-month ROA as well as cash money from operations are adverse 100.6% and $31.33 million, specifically. Moreover, its trailing-12-month gross profit margin, ROE as well as ROTC are adverse 18.9%, 115%, as well as 67%, respectively. As well as its 0.12% possession turnover proportion is 65.2% less than the 0.34% industry average.

Failing Financials
RMED’s web income from continuing operations was available in at $5,000 for the third quarter, finished Sept. 30, 2021, versus $68,000 in the 3rd quarter of 2020. Its gross loss stood at $24,000 for the quarter, while operating loss was available in at $7.39 million. Moreover, its net loss amounted to $4.3 million, while its loss per share was available in at $0.67. RMED reported a negative adjusted EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. As well as its complete operating expenses grew 2.1% year-over-year to $7.15 million during this period.

POWR Ratings Show Bleak Prospects

RMED has a total D score, which equates to Market in our POWR Rankings system. The POWR Rankings are computed by thinking about 118 distinct elements, with each factor heavy to an ideal degree.

Our exclusive rating system additionally evaluates each stock based upon 8 unique groups. RMED has an F grade for Quality. This reflects the stock’s adverse ROA and also capital from operations.

The firm has a D grade in Momentum, constant with its price decrease over the past 6 months. Also, it has an F quality for Stability, which remains in sync with its reasonably high beta of 1.65.

Past the qualities I have actually highlighted, one can check out additional RMED rankings for Belief, Development, and also Worth right here. Among the 166 stocks in the D-rated Medical– Gadget & Tools industry, RMED is placed # 119.

Profits

Analysts expect RMED’s EPS to stay unfavorable this year. While its efforts to develop DABRA catheters bode well, its adverse earnings margin as well as inadequate monetary strength might cause its shares to decline better. Moreover, the unpredictability surrounding the regulative clearance and also commercialization of its DABRA laser system might elevate investors’ concerns. So, we think it is finest prevented currently.

Exactly How Does Ra Medical Systems (RMED) Stack Up Against its Peers?

While RMED has an overall D (Offer) ranking in our proprietary rating system, one might intend to consider taking a look at its sector peers, Fonar Firm (FONR – Obtain Rating), Electromed, Inc. (ELMD – Obtain Ranking), and Abbott Laboratories (ABT – Get Score), having an A (Solid Buy) rating.

Related Posts

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top